vTv Therapeutics Inc.
About vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$27.0M
- Total assets
- $89.9M
- Market cap
- $126.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $32.8M
- Operating income
- -$32.8M
- Income tax
- $0
- Net income
- -$31.1M
Balance sheet
- Total assets
- $89.9M
- Current assets
- $89.9M
- Total liabilities
- $25.5M
- Current liabilities
- $6.6M
- Shareholders’ equity
- $64.4M
Cash flow
- Operating cash flow
- -$25.3M
- Investing cash flow
- -$52.2M
- Financing cash flow
- $77.4M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $126.6M
- Shares outstanding
- 4.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 30, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $27.0M in FY2025.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review vTv Therapeutics Inc..
Write a review
News about vTv Therapeutics Inc.
News & sentiment via Polygon.io
